Browsing: Lorlatinib

Treatments

Lorlatinib Improves Long-Term Efficacy in Advanced ALK+ NSCLC

By NewsCancerJune 2, 20260

Lorlatinib (Lorbrena) improved long-term efficacy outcomes vs crizotinib (Xalkori) among patients with advanced ALK-positive non–small cell lung cancer, according to…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

How Cheating Death Changed My Perspective on Life

Anbenitamab Regimen Meets Phase 3 End Points in HER2+ Breast Cancer

AI 'filling in gaps' in lung cancer diagnoses

Browsing: Lorlatinib

Lorlatinib Improves Long-Term Efficacy in Advanced ALK+ NSCLC

How Cheating Death Changed My Perspective on Life

Anbenitamab Regimen Meets Phase 3 End Points in HER2+ Breast Cancer

AI 'filling in gaps' in lung cancer diagnoses

Ovarian cancer drug approved for NHS use will prolong lives

How Cheating Death Changed My Perspective on Life

Anbenitamab Regimen Meets Phase 3 End Points in HER2+ Breast Cancer

AI 'filling in gaps' in lung cancer diagnoses

Ovarian cancer drug approved for NHS use will prolong lives

Latest Post

How Cheating Death Changed My Perspective on Life

Anbenitamab Regimen Meets Phase 3 End Points in HER2+ Breast Cancer

AI 'filling in gaps' in lung cancer diagnoses

Subscribe to Updates

What's Hot

Browsing: Lorlatinib